Document Type

Journal Article

Publication Title

Alzheimer's and Dementia

PubMed ID

36349985

Publisher

Wiley

School

School of Medical and Health Sciences / Centre of Excellence for Alzheimer's Disease Research and Care

RAS ID

54152

Funders

National Health and Medical Research Council

Australian Research Council, Future Fellowship

Ministry of Science and Technology of China, Grant Number: SQ2018YFC200022

Bethlehem Griffiths Research Foundation, Grant Number: BGRF1901

Victorian Government's Operational Infrastructure

Florey Institute

NIH. Grant Numbers: AG058252, AG073979, AG051848

Grant Number

NHMRC Numbers: 1048082, 1061419, 1120095, 110178ARC Number : FT120100581

Comments

Huang, X., Li, Y., Fowler, C., Doecke, J. D., Lim, Y. Y., Drysdale, C., ... & Gu, B. J. (2023). Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. Alzheimer's & Dementia, 19(5), 2084-2094.

https://doi.org/10.1002/alz.12813

Abstract

Introduction:

Blood-based diagnostics and prognostics in sporadic Alzheimer's disease (AD) are important for identifying at-risk individuals for therapeutic interventions.

Methods:

In three stages, a total of 34 leukocyte antigens were examined by flow cytometry immunophenotyping. Data were analyzed by logistic regression and receiver operating characteristic (ROC) analyses.

Results:

We identified leukocyte markers differentially expressed in the patients with AD. Pathway analysis revealed a complex network involving upregulation of complement inhibition and downregulation of cargo receptor activity and Aβ clearance. A proposed panel including four leukocyte markers – CD11c, CD59, CD91, and CD163 – predicts patients’ PET Aβ status with an area under the curve (AUC) of 0.93 (0.88 to 0.97). CD163 was the top performer in preclinical models. These findings have been validated in two independent cohorts.

Conclusion:

Our finding of changes on peripheral leukocyte surface antigens in AD implicates the deficit in innate immunity. Leukocyte-based biomarkers prove to be both sensitive and practical for AD screening and diagnosis.

DOI

10.1002/alz.12813

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Included in

Diagnosis Commons

Share

 
COinS